P. Fenaux, C. Chastang, and S. Chevret, A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group, Blood, vol.14, pp.1192-1200, 1999.

M. Sanz, G. Martin, and M. Gonzalez, Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group, Blood, vol.103, issue.4, pp.1237-1243, 2004.
DOI : 10.1182/blood-2003-07-2462

F. Mandelli, D. Diverio, and G. Avvisati, Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups, Blood, vol.90, pp.1014-1021, 1997.

M. Sanz, D. Grimwade, and M. Tallman, Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet, Blood, vol.113, issue.9, pp.1875-1891, 2009.
DOI : 10.1182/blood-2008-04-150250

F. Coco, G. Cimino, and M. Breccia, Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia, Blood, vol.104, issue.7, pp.1995-1999, 2004.
DOI : 10.1182/blood-2004-04-1550

W. Au, C. Chim, and A. Lie, Treatment of relapsed acute promyelocytic leukemia by arsenic-based strategies without hematopoietic stem cell transplantation in Hong Kong: a seven-year experience, Blood, vol.104, 2004.

W. Au, C. Kumana, and M. Kou, Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia, Blood, vol.102, issue.1, pp.407-408, 2003.
DOI : 10.1182/blood-2003-01-0298

R. Jeddi, S. Hdiji, and K. Kacem, Therapeutic results with APL 93 protocol in acute promyelocytic leukemia (34 cases)], Tunis Med, vol.84, pp.717-720, 2006.

M. Sanz, L. Coco, F. Martin, and G. , Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups, Blood, vol.96, pp.1247-1253, 2000.

L. Adès, S. Chevret, and E. Raffoux, Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group, Journal of Clinical Oncology, vol.24, issue.36, pp.5703-5710, 2006.
DOI : 10.1200/JCO.2006.08.1596

E. Lengfelder, C. Haferlach, and S. Saussele, High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG, Leukemia, vol.95, issue.12, pp.2248-2258, 2009.
DOI : 10.1182/blood-2008-07-168617

E. Lengfelder, S. Saussele, and T. Haferlach, Treatment of newly diagnosed acute promyelocytic leukemia: the impact of high dose ara-C, Blood, vol.102, p.448, 2003.

L. Adès, M. Sanz, and S. Chevret, Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results, Blood, vol.111, issue.3, pp.1078-1084, 2008.
DOI : 10.1182/blood-2007-07-099978

A. Burnett, D. Grimwade, and E. Solomon, Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial, Blood, vol.93, pp.4131-4143, 1999.

L. De, J. Serna, P. Montesinos, and E. Vellenga, Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin, Blood, vol.11, pp.3395-3402, 2008.

M. Tallman, J. Andersen, and C. Schiffer, Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome, Blood, vol.95, pp.90-95, 2000.

P. Montesinos, J. Berqua, and E. Vellenga, Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors, Blood, vol.113, issue.4, pp.775-783, 2009.
DOI : 10.1182/blood-2008-07-168617

R. Jeddi, H. Ghédira, S. Mnif, E. Gouider, P. Fenaux et al., High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia, Leukemia Research, vol.34, issue.4, pp.545-547, 2010.
DOI : 10.1016/j.leukres.2009.09.017

S. Botton, H. Dombret, and M. Sanz, Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia, Blood, vol.92, pp.2712-2727, 1998.

E. Estey, P. Thall, and H. Kantarjian, Association between increased body mass index and a diagnosis of acute promyelocytic leukemia

M. Konopleva, A. Mikhail, and Z. Estov, Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptic activities, Blood, vol.93, pp.1668-1676, 1999.

Y. Tabe, M. Konopleva, and M. Munsell, PML-RAR?? is associated with leptin-receptor induction: the role of mesenchymal stem cell-derived adipocytes in APL cell survival, Blood, vol.103, issue.5, pp.1815-1822, 2004.
DOI : 10.1182/blood-2003-03-0802

G. Lazo, H. Kantarjian, and E. Estey, Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia, Cancer, vol.98, issue.9, pp.2218-2224, 2003.
DOI : 10.1002/cncr.11314

C. Niu, H. Yan, and T. Yu, Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients, Blood, vol.94, pp.3315-3324, 1999.

S. Soignet, S. Frankel, and D. Douer, United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia, Journal of Clinical Oncology, vol.19, issue.18, pp.3852-3860, 2001.
DOI : 10.1200/JCO.2001.19.18.3852

G. Meloni, D. Diverio, and M. Vignetti, Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene, Blood, vol.90, pp.1321-1325, 1997.

S. De-botton, A. Fawaz, and S. Chevret, -Retinoic Acid: A Retrospective Analysis of the European Acute Promyelocytic Leukemia Group, Journal of Clinical Oncology, vol.23, issue.1, pp.120-126, 2005.
DOI : 10.1200/JCO.2005.03.127

URL : https://hal.archives-ouvertes.fr/jpa-00214712

C. Linker, Autologous stem cell transplantation for acute myeloid leukemia, Bone Marrow Transplantation, vol.31, issue.9, pp.731-738, 2003.
DOI : 10.1038/sj.bmt.1704020

F. Lo-coco, A. Romano, and A. Mengarelli, Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease, Leukemia, vol.17, issue.10, pp.1930-1933, 2003.
DOI : 10.1038/sj.leu.2403078

M. Sanz, M. Labopin, and N. Gorin, Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation, Bone Marrow Transplantation, vol.103, issue.8, pp.461-469, 2007.
DOI : 10.1038/sj.bmt.1705620

R. Latagliata, M. Petti, S. Fanu, M. Mancini, A. Spiritti et al., Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem, Blood, vol.99, issue.3, pp.822-824, 2002.
DOI : 10.1182/blood.V99.3.822

I. Lobe, F. Huguet, and A. Vekhoff, Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience, Leukemia, vol.17, issue.8, pp.1600-1604, 2003.
DOI : 10.1038/sj.leu.2403034

R. Jeddi, E. Gouider, B. Neji, and H. , Secondary chronic myelomonocytic leukemia with monosomy 7 after successful treatment of acute promyelocytic leukemia, Pathologie Biologie, vol.56, issue.3, pp.162-163, 2009.
DOI : 10.1016/j.patbio.2007.09.005